Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events
Cardiac and cerebral vascular diseases are leading causes of morbidity and death in solid organ transplant recipients. Immunosuppressant drugs are associated with dyslipidemia, hypertension, and hyperglycemia, which along with obesity are the main features of metabolic syndrome. In the nontransplant...
Gespeichert in:
| Veröffentlicht in: | Liver transplantation 2007-08, Vol.13 (8), p.1109-1114 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1114 |
|---|---|
| container_issue | 8 |
| container_start_page | 1109 |
| container_title | Liver transplantation |
| container_volume | 13 |
| creator | Laryea, Marie Watt, Kymberly D. Molinari, Michele Walsh, Mark J. McAlister, Vivian C. Marotta, Paul J. Nashan, Bjorn Peltekian, Kevork M. |
| description | Cardiac and cerebral vascular diseases are leading causes of morbidity and death in solid organ transplant recipients. Immunosuppressant drugs are associated with dyslipidemia, hypertension, and hyperglycemia, which along with obesity are the main features of metabolic syndrome. In the nontransplant population, metabolic syndrome is associated with increased risk for major vascular complications. We postulated that metabolic syndrome is common post–liver transplantation and plays a significant role leading to cardiac and cerebrovascular events. Our Multi‐Organ Transplant Program database was reviewed for all liver transplant recipients between January 1998 and June 2004 with follow‐up until December 2005. We adapted the 2001 National Cholesterol Education Program‐Adult Treatment Panel III Guidelines to define posttransplantation metabolic syndrome (PTMS) as the presence at least 3 of the following: 1) obesity (body mass index >30 kg/m2); 2) serum triglyceride level ≥1.7 mmol/L; 3) high density lipoprotein level |
| doi_str_mv | 10.1002/lt.21126 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68127308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68127308</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-c563464a02af363cb36de696482e2b7b6ed3203cc33ab1c5b1b2cfc3f1207be13</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqUg8QXIK8Qm4EfitOxQxUsqgkVZR7YzUV05cbGdVP17UlLBitXM4tyjmYvQJSW3lBB2Z-Mto5SJIzSmGcsTkeb8-HcX2QidhbAmhNJsRk7RiOZC8JTSMVq9QZTKWaNx2DWldzVg02BrOvA4etmEjZVNxB602RhoYrjHHx46aaHRgGVTYhmC00ZG4xq8NXGFa7l2Hncy6NZKj6Hbx87RSSVtgIvDnKDPp8fl_CVZvD-_zh8WieYZF4nO-sNEKgmTFRdcKy5KEDORThkwlSsBJWeEa825VFRniiqmK80rykiugPIJuh68G---WgixqE3QYPsvwLWhEFPKck6mPXgzgNq7EDxUxcabWvpdQUmxb7WwsfhptUevDs5W1VD-gYcaeyAZgK2xsPtXVCyWg_AbhmSCGg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68127308</pqid></control><display><type>article</type><title>Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Laryea, Marie ; Watt, Kymberly D. ; Molinari, Michele ; Walsh, Mark J. ; McAlister, Vivian C. ; Marotta, Paul J. ; Nashan, Bjorn ; Peltekian, Kevork M.</creator><creatorcontrib>Laryea, Marie ; Watt, Kymberly D. ; Molinari, Michele ; Walsh, Mark J. ; McAlister, Vivian C. ; Marotta, Paul J. ; Nashan, Bjorn ; Peltekian, Kevork M.</creatorcontrib><description>Cardiac and cerebral vascular diseases are leading causes of morbidity and death in solid organ transplant recipients. Immunosuppressant drugs are associated with dyslipidemia, hypertension, and hyperglycemia, which along with obesity are the main features of metabolic syndrome. In the nontransplant population, metabolic syndrome is associated with increased risk for major vascular complications. We postulated that metabolic syndrome is common post–liver transplantation and plays a significant role leading to cardiac and cerebrovascular events. Our Multi‐Organ Transplant Program database was reviewed for all liver transplant recipients between January 1998 and June 2004 with follow‐up until December 2005. We adapted the 2001 National Cholesterol Education Program‐Adult Treatment Panel III Guidelines to define posttransplantation metabolic syndrome (PTMS) as the presence at least 3 of the following: 1) obesity (body mass index >30 kg/m2); 2) serum triglyceride level ≥1.7 mmol/L; 3) high density lipoprotein level <1 mmol/L in men and <1.3 mmol/L in women; 4) hypertension; and 5) fasting plasma glucose ≥5.6 mmol/L. A total of 118 patients were included. Among them, 69 patients (58%) had PTMS. The mean (± standard deviation) time from transplant was 59 ± 21 months (no significant difference in patients with or without metabolic syndrome). Overall, patients with metabolic syndrome had a significantly higher average age, posttransplantation body mass index, fasting glucose, high‐density lipoprotein levels, and serum triglycerides. There was no difference in creatinine, hemoglobin, or prednisone average dose between the 2 groups. There were 25 major vascular events affecting 21% of patients. There were significantly more vascular events in patients with metabolic syndrome posttransplantation than in those without (30% vs. 8%; P = 0.003) during the study period. In conclusion, the prevalence of metabolic syndrome post–liver transplant is significantly higher than that estimated in the general population. Metabolic syndrome appears to be associated with an increased risk of major vascular events in our liver transplant population. Liver Transpl 13:1109–1114, 2007. © 2007 AASLD.</description><identifier>ISSN: 1527-6465</identifier><identifier>EISSN: 1527-6473</identifier><identifier>DOI: 10.1002/lt.21126</identifier><identifier>PMID: 17663411</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Female ; Humans ; Insulin Resistance ; Liver - pathology ; Liver Failure - surgery ; Liver Transplantation - adverse effects ; Liver Transplantation - methods ; Male ; Metabolic Syndrome - complications ; Metabolic Syndrome - diagnosis ; Metabolic Syndrome - etiology ; Middle Aged ; Prevalence ; Time Factors ; Triglycerides - metabolism ; Vascular Diseases - diagnosis ; Vascular Diseases - etiology</subject><ispartof>Liver transplantation, 2007-08, Vol.13 (8), p.1109-1114</ispartof><rights>Copyright © 2007 American Association for the Study of Liver Diseases</rights><rights>Copyright (c) 2007 AASLD.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-c563464a02af363cb36de696482e2b7b6ed3203cc33ab1c5b1b2cfc3f1207be13</citedby><cites>FETCH-LOGICAL-c3536-c563464a02af363cb36de696482e2b7b6ed3203cc33ab1c5b1b2cfc3f1207be13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Flt.21126$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Flt.21126$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17663411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laryea, Marie</creatorcontrib><creatorcontrib>Watt, Kymberly D.</creatorcontrib><creatorcontrib>Molinari, Michele</creatorcontrib><creatorcontrib>Walsh, Mark J.</creatorcontrib><creatorcontrib>McAlister, Vivian C.</creatorcontrib><creatorcontrib>Marotta, Paul J.</creatorcontrib><creatorcontrib>Nashan, Bjorn</creatorcontrib><creatorcontrib>Peltekian, Kevork M.</creatorcontrib><title>Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events</title><title>Liver transplantation</title><addtitle>Liver Transpl</addtitle><description>Cardiac and cerebral vascular diseases are leading causes of morbidity and death in solid organ transplant recipients. Immunosuppressant drugs are associated with dyslipidemia, hypertension, and hyperglycemia, which along with obesity are the main features of metabolic syndrome. In the nontransplant population, metabolic syndrome is associated with increased risk for major vascular complications. We postulated that metabolic syndrome is common post–liver transplantation and plays a significant role leading to cardiac and cerebrovascular events. Our Multi‐Organ Transplant Program database was reviewed for all liver transplant recipients between January 1998 and June 2004 with follow‐up until December 2005. We adapted the 2001 National Cholesterol Education Program‐Adult Treatment Panel III Guidelines to define posttransplantation metabolic syndrome (PTMS) as the presence at least 3 of the following: 1) obesity (body mass index >30 kg/m2); 2) serum triglyceride level ≥1.7 mmol/L; 3) high density lipoprotein level <1 mmol/L in men and <1.3 mmol/L in women; 4) hypertension; and 5) fasting plasma glucose ≥5.6 mmol/L. A total of 118 patients were included. Among them, 69 patients (58%) had PTMS. The mean (± standard deviation) time from transplant was 59 ± 21 months (no significant difference in patients with or without metabolic syndrome). Overall, patients with metabolic syndrome had a significantly higher average age, posttransplantation body mass index, fasting glucose, high‐density lipoprotein levels, and serum triglycerides. There was no difference in creatinine, hemoglobin, or prednisone average dose between the 2 groups. There were 25 major vascular events affecting 21% of patients. There were significantly more vascular events in patients with metabolic syndrome posttransplantation than in those without (30% vs. 8%; P = 0.003) during the study period. In conclusion, the prevalence of metabolic syndrome post–liver transplant is significantly higher than that estimated in the general population. Metabolic syndrome appears to be associated with an increased risk of major vascular events in our liver transplant population. Liver Transpl 13:1109–1114, 2007. © 2007 AASLD.</description><subject>Female</subject><subject>Humans</subject><subject>Insulin Resistance</subject><subject>Liver - pathology</subject><subject>Liver Failure - surgery</subject><subject>Liver Transplantation - adverse effects</subject><subject>Liver Transplantation - methods</subject><subject>Male</subject><subject>Metabolic Syndrome - complications</subject><subject>Metabolic Syndrome - diagnosis</subject><subject>Metabolic Syndrome - etiology</subject><subject>Middle Aged</subject><subject>Prevalence</subject><subject>Time Factors</subject><subject>Triglycerides - metabolism</subject><subject>Vascular Diseases - diagnosis</subject><subject>Vascular Diseases - etiology</subject><issn>1527-6465</issn><issn>1527-6473</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EoqUg8QXIK8Qm4EfitOxQxUsqgkVZR7YzUV05cbGdVP17UlLBitXM4tyjmYvQJSW3lBB2Z-Mto5SJIzSmGcsTkeb8-HcX2QidhbAmhNJsRk7RiOZC8JTSMVq9QZTKWaNx2DWldzVg02BrOvA4etmEjZVNxB602RhoYrjHHx46aaHRgGVTYhmC00ZG4xq8NXGFa7l2Hncy6NZKj6Hbx87RSSVtgIvDnKDPp8fl_CVZvD-_zh8WieYZF4nO-sNEKgmTFRdcKy5KEDORThkwlSsBJWeEa825VFRniiqmK80rykiugPIJuh68G---WgixqE3QYPsvwLWhEFPKck6mPXgzgNq7EDxUxcabWvpdQUmxb7WwsfhptUevDs5W1VD-gYcaeyAZgK2xsPtXVCyWg_AbhmSCGg</recordid><startdate>200708</startdate><enddate>200708</enddate><creator>Laryea, Marie</creator><creator>Watt, Kymberly D.</creator><creator>Molinari, Michele</creator><creator>Walsh, Mark J.</creator><creator>McAlister, Vivian C.</creator><creator>Marotta, Paul J.</creator><creator>Nashan, Bjorn</creator><creator>Peltekian, Kevork M.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200708</creationdate><title>Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events</title><author>Laryea, Marie ; Watt, Kymberly D. ; Molinari, Michele ; Walsh, Mark J. ; McAlister, Vivian C. ; Marotta, Paul J. ; Nashan, Bjorn ; Peltekian, Kevork M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-c563464a02af363cb36de696482e2b7b6ed3203cc33ab1c5b1b2cfc3f1207be13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Female</topic><topic>Humans</topic><topic>Insulin Resistance</topic><topic>Liver - pathology</topic><topic>Liver Failure - surgery</topic><topic>Liver Transplantation - adverse effects</topic><topic>Liver Transplantation - methods</topic><topic>Male</topic><topic>Metabolic Syndrome - complications</topic><topic>Metabolic Syndrome - diagnosis</topic><topic>Metabolic Syndrome - etiology</topic><topic>Middle Aged</topic><topic>Prevalence</topic><topic>Time Factors</topic><topic>Triglycerides - metabolism</topic><topic>Vascular Diseases - diagnosis</topic><topic>Vascular Diseases - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laryea, Marie</creatorcontrib><creatorcontrib>Watt, Kymberly D.</creatorcontrib><creatorcontrib>Molinari, Michele</creatorcontrib><creatorcontrib>Walsh, Mark J.</creatorcontrib><creatorcontrib>McAlister, Vivian C.</creatorcontrib><creatorcontrib>Marotta, Paul J.</creatorcontrib><creatorcontrib>Nashan, Bjorn</creatorcontrib><creatorcontrib>Peltekian, Kevork M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Liver transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laryea, Marie</au><au>Watt, Kymberly D.</au><au>Molinari, Michele</au><au>Walsh, Mark J.</au><au>McAlister, Vivian C.</au><au>Marotta, Paul J.</au><au>Nashan, Bjorn</au><au>Peltekian, Kevork M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events</atitle><jtitle>Liver transplantation</jtitle><addtitle>Liver Transpl</addtitle><date>2007-08</date><risdate>2007</risdate><volume>13</volume><issue>8</issue><spage>1109</spage><epage>1114</epage><pages>1109-1114</pages><issn>1527-6465</issn><eissn>1527-6473</eissn><abstract>Cardiac and cerebral vascular diseases are leading causes of morbidity and death in solid organ transplant recipients. Immunosuppressant drugs are associated with dyslipidemia, hypertension, and hyperglycemia, which along with obesity are the main features of metabolic syndrome. In the nontransplant population, metabolic syndrome is associated with increased risk for major vascular complications. We postulated that metabolic syndrome is common post–liver transplantation and plays a significant role leading to cardiac and cerebrovascular events. Our Multi‐Organ Transplant Program database was reviewed for all liver transplant recipients between January 1998 and June 2004 with follow‐up until December 2005. We adapted the 2001 National Cholesterol Education Program‐Adult Treatment Panel III Guidelines to define posttransplantation metabolic syndrome (PTMS) as the presence at least 3 of the following: 1) obesity (body mass index >30 kg/m2); 2) serum triglyceride level ≥1.7 mmol/L; 3) high density lipoprotein level <1 mmol/L in men and <1.3 mmol/L in women; 4) hypertension; and 5) fasting plasma glucose ≥5.6 mmol/L. A total of 118 patients were included. Among them, 69 patients (58%) had PTMS. The mean (± standard deviation) time from transplant was 59 ± 21 months (no significant difference in patients with or without metabolic syndrome). Overall, patients with metabolic syndrome had a significantly higher average age, posttransplantation body mass index, fasting glucose, high‐density lipoprotein levels, and serum triglycerides. There was no difference in creatinine, hemoglobin, or prednisone average dose between the 2 groups. There were 25 major vascular events affecting 21% of patients. There were significantly more vascular events in patients with metabolic syndrome posttransplantation than in those without (30% vs. 8%; P = 0.003) during the study period. In conclusion, the prevalence of metabolic syndrome post–liver transplant is significantly higher than that estimated in the general population. Metabolic syndrome appears to be associated with an increased risk of major vascular events in our liver transplant population. Liver Transpl 13:1109–1114, 2007. © 2007 AASLD.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>17663411</pmid><doi>10.1002/lt.21126</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1527-6465 |
| ispartof | Liver transplantation, 2007-08, Vol.13 (8), p.1109-1114 |
| issn | 1527-6465 1527-6473 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68127308 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Female Humans Insulin Resistance Liver - pathology Liver Failure - surgery Liver Transplantation - adverse effects Liver Transplantation - methods Male Metabolic Syndrome - complications Metabolic Syndrome - diagnosis Metabolic Syndrome - etiology Middle Aged Prevalence Time Factors Triglycerides - metabolism Vascular Diseases - diagnosis Vascular Diseases - etiology |
| title | Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A57%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolic%20syndrome%20in%20liver%20transplant%20recipients:%20Prevalence%20and%20association%20with%20major%20vascular%20events&rft.jtitle=Liver%20transplantation&rft.au=Laryea,%20Marie&rft.date=2007-08&rft.volume=13&rft.issue=8&rft.spage=1109&rft.epage=1114&rft.pages=1109-1114&rft.issn=1527-6465&rft.eissn=1527-6473&rft_id=info:doi/10.1002/lt.21126&rft_dat=%3Cproquest_cross%3E68127308%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68127308&rft_id=info:pmid/17663411&rfr_iscdi=true |